Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12621001366842
Ethics application status
Approved
Date submitted
30/08/2021
Date registered
11/10/2021
Date last updated
28/09/2022
Date data sharing statement initially provided
11/10/2021
Type of registration
Retrospectively registered
Titles & IDs
Public title
Vaginal Oestriol to prevent vaginal stenosis (VESPA).
Query!
Scientific title
A phase II pilot study of the use of vaginal oestriol to prevent vaginal stenosis in patients treated with radiotherapy for gynaecological, rectal and anal malignancies.
Query!
Secondary ID [1]
304854
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
VESPA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Vaginal stenosis following radiotherapy
322952
0
Query!
Condition category
Condition code
Cancer
320525
320525
0
0
Query!
Cervical (cervix)
Query!
Cancer
320629
320629
0
0
Query!
Womb (Uterine or endometrial cancer)
Query!
Cancer
320631
320631
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Cancer
320632
320632
0
0
Query!
Bowel - Anal
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Application of vaginal oestriol topical cream to prevent vaginal stenosis in women receiving radiotherapy for gynecological, rectal and anal malignancies.
Patient will commence the study drug 2 weeks post completion of pelvic radiotherapy treatment along with instructions for use and/or demonstration of oestriol applicator use by the clinician or clinic nurse.
Participants will be instructed to insert the applicator with a dose of 0.5 mg of the study drug Oestriol 0.1% (1mg per g topical cream) to the top of the vagina daily for the first two weeks and then twice weekly for the rest of the intervention period (12 months application of oestriol).
Information about compliance with the intervention will be collected at scheduled visits (1, 3, 6,9, 12 month after start of oestriol) using the Adherence and Disruption
Questionnaire.
Query!
Intervention code [1]
321309
0
Prevention
Query!
Intervention code [2]
321729
0
Treatment: Drugs
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
328444
0
Feasibility, compliance and acceptability of the use of vaginal oestriol, as measured by adherence and disruption questionnaire (ADQ). This will be assessed as a composite outcome.
Query!
Assessment method [1]
328444
0
Query!
Timepoint [1]
328444
0
12 months post end of radiotherapy
Query!
Primary outcome [2]
328445
0
The incidence of stenosis as measured by the LENT-SOMA scale on the basis of clinical assessment.
Query!
Assessment method [2]
328445
0
Query!
Timepoint [2]
328445
0
12 months post end of radiotherapy
Query!
Primary outcome [3]
328446
0
Safety - measured using the serum levels of oestradiol and FSH in blood tests taken at regular intervals.
Query!
Assessment method [3]
328446
0
Query!
Timepoint [3]
328446
0
Assessed at every treatment appointment up to 12 months post end of radiotherapy
Query!
Secondary outcome [1]
399032
0
Sexual function and vaginal symptoms - measured by the Sexual-function-Vaginal changes Questionnaire (SVQ). This will be assessed as a composite outcome.
Query!
Assessment method [1]
399032
0
Query!
Timepoint [1]
399032
0
12 months post end of radiotherapy
Query!
Secondary outcome [2]
399033
0
Health-related quality of life – patient reported outcome measures (FACT-G)
Query!
Assessment method [2]
399033
0
Query!
Timepoint [2]
399033
0
12 months post end of radiotherapy
Query!
Secondary outcome [3]
401015
0
Safety – measured by the collection and analysis of Serious Adverse Events and Adverse Events.
Query!
Assessment method [3]
401015
0
Query!
Timepoint [3]
401015
0
Assessed at every treatment appointment up to 12 months post end of radiotherapy, or 4 weeks after last study treatment if patients discontinues due to Adverse Event. Assessed via study-specific form including CTCAE grading.
Query!
Eligibility
Key inclusion criteria
1. confirmed diagnosis of gynaecological, rectal or anal cancer
2. received external beam radiotherapy, with curative intent to the pelvis, (both primary treatment and neo/adjuvant treatment) of at least 45 gray in 25 fractions, or equivalent
3. aged 18 years or older
4. able to read and write English, and give written, informed consent
5. able to complete quality of life instruments
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. severe psychiatric, cognitive or physical disorder that would preclude them from inserting an applicator
2. receiving radiotherapy for recurrent disease
3. had estrogen receptor positive breast cancer within last 5 years
4. currently on hormone replacement therapy (HRT).Those patients who were previously on hormone replacement therapy can go into the study as long as they have ceased the HRT at least 4 weeks prior to entry into the study
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
For this phase II pilot, based on Simon’s two-stage design, 30 patients provide 80% power with 95% confidence to rule out a 25-30% stenosis rate in favour of a 7-10% with the use of vaginal oestriol.
Summary measures will include frequencies and proportions presented with their corresponding 95% confidence intervals. Comparisons of proportions will be performed using chi-squared or exact tests (e.g., conditional binomial) and continuous outcomes will be analyzed by using t-tests or suitable non-parametric methods if appropriate. For binary outcomes logistic regression analysis will be employed where adjustment for prognostic factors is mediated.
Stenosis free survival will be analyzed using time-to-event methods including the log-rank test and Cox proportional hazards regression models. Kaplan-Meier survival curves will be constructed for graphical display. Actuarial event-free survival rates will also be calculated with suitable 95% confidence intervals.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
28/05/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
45
Query!
Accrual to date
30
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Query!
Recruitment hospital [1]
20115
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [2]
20116
0
Calvary Mater Newcastle - Waratah
Query!
Recruitment hospital [3]
20117
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [4]
20118
0
Gold Coast University Hospital - Southport
Query!
Recruitment hospital [5]
20119
0
Royal Brisbane & Womens Hospital - Herston
Query!
Recruitment hospital [6]
20530
0
Prince of Wales Private Hospital - Randwick
Query!
Recruitment postcode(s) [1]
34823
0
2145 - Westmead
Query!
Recruitment postcode(s) [2]
34824
0
2298 - Waratah
Query!
Recruitment postcode(s) [3]
34825
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [4]
34826
0
4215 - Southport
Query!
Recruitment postcode(s) [5]
34827
0
4029 - Herston
Query!
Recruitment postcode(s) [6]
35312
0
2031 - Randwick
Query!
Funding & Sponsors
Funding source category [1]
309227
0
Hospital
Query!
Name [1]
309227
0
Westmead Hospital, Department of Gynaecological Oncology
Query!
Address [1]
309227
0
Westmead Hospital
PO Box 533, Wentworthville, NSW 2145
Query!
Country [1]
309227
0
Australia
Query!
Funding source category [2]
309293
0
Government body
Query!
Name [2]
309293
0
Cancer Institute NSW via SWTCRC
Query!
Address [2]
309293
0
Sydney West Translational Cancer Research Centre
Westmead Hospital
PO Box 533, Wentworthville, NSW 2145
Query!
Country [2]
309293
0
Australia
Query!
Primary sponsor type
Government body
Query!
Name
Western Sydney Local Health District
Query!
Address
Westmead Hospital
PO Box 533, Wentworthville, NSW 2145
Query!
Country
Australia
Query!
Secondary sponsor category [1]
310328
0
None
Query!
Name [1]
310328
0
Query!
Address [1]
310328
0
Query!
Country [1]
310328
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
309075
0
Western Sydney Local Health District HREC
Query!
Ethics committee address [1]
309075
0
Research and Education Network
Westmead Hospital, PO Box 533, Wentworthville, NSW 2145
Query!
Ethics committee country [1]
309075
0
Australia
Query!
Date submitted for ethics approval [1]
309075
0
Query!
Approval date [1]
309075
0
05/03/2014
Query!
Ethics approval number [1]
309075
0
Query!
Summary
Brief summary
The primary purpose of this study is to assess the feasibility, safety, and activity of vaginal oestriol in preventing vaginal stenosis in women receiving radiotherapy for gynecological, rectal and anal malignancies.
Who is it for?
You may be eligible for this study if you are a woman aged 18 years or above, who has received external beam radiotherapy, with curative intent to the pelvis, for treatment of a confirmed diagnosis of gynaecological, rectal or anal cancer.
Study details
Participants will be asked to regularly apply vaginal oestriol cream following completion of pelvic radiotherapy, and will be followed up for safety and effectiveness.
It is hoped that information from this study will help improve health-related quality of life for women after cancer treatment for gynecological, rectal and anal malignancies.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
112886
0
A/Prof Alison Brand
Query!
Address
112886
0
Department of Gynaecological Oncology
Westmead Hospital
PO Box 533,
Wentworthville, NSW 2145
Query!
Country
112886
0
Australia
Query!
Phone
112886
0
+61 2 8890 6801
Query!
Fax
112886
0
Query!
Email
112886
0
[email protected]
Query!
Contact person for public queries
Name
112887
0
Ms Kate Campbell
Query!
Address
112887
0
Department of Gynaecological Oncology
Westmead Hospital
PO Box 533,
Wentworthville, NSW 2145
Query!
Country
112887
0
Australia
Query!
Phone
112887
0
+61 2 8890 6347
Query!
Fax
112887
0
Query!
Email
112887
0
[email protected]
Query!
Contact person for scientific queries
Name
112888
0
Ms Kate Campbell
Query!
Address
112888
0
Department of Gynaecological Oncology
Westmead Hospital
PO Box 533,
Wentworthville, NSW 2145
Query!
Country
112888
0
Australia
Query!
Phone
112888
0
+61 2 8890 6347
Query!
Fax
112888
0
Query!
Email
112888
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF